Conexeu Sciences Inc. 8-K

What Happened

• Conexeu Sciences Inc. filed an 8-K reporting the exercise of outstanding warrants and related issuances in early June 2026. On June 4, 2026 the company issued 416,667 common shares upon exercise of an equal number of warrants and also issued 416,667 transferable Incentive Warrants under an Incentive Program. On June 8, 2026 the company issued 100,000 common shares upon exercise of performance warrants. Total common shares issued from these exercises: 516,667. Proceeds were approximately $166,667 from the June 4 exercises and $100 from the June 8 exercise.

Key Details

• 416,667 Warrant Shares issued on June 4, 2026; gross proceeds ~$166,667.
• 416,667 Incentive Warrants issued on June 4 under the Incentive Program; each Incentive Warrant allows purchase of one share at $2.30 for 36 months. Additional shares from these Incentive Warrants are not registered.
• 100,000 Performance Warrant Shares issued on June 8, 2026 at $0.001 per share for $100.
• Shares outstanding: 26,658,330 after the June 4 exercises, and 26,758,330 after the June 8 exercises. Following the June 4 activity, 410,338 Program Warrants remained outstanding.
• Securities issued on June 4 relied on Regulation S (Rule 903(b)) for a non-U.S. person; the June 8 issuance relied on Section 4(a)(2) and Rule 506(b) of Regulation D for a U.S. person.

Why It Matters

• These transactions slightly increase the company’s shares outstanding (dilution) and bring modest cash to the company (about $166,767 total reported).
• The Incentive Warrants introduce potential future dilution if exercised (exercise price $2.30, 36‑month term) and those Additional Warrant Shares are not currently registered.
• Investors should note the types of registration exemptions used and the remaining outstanding warrants, which may affect future share count and capital if further exercises occur.